LIBTAYO demonstrated meaningful tumor reduction in clinical trial patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who were not candidates for curative surgery or curative radiation1,2
Patient responses
These are examples from the 31% of patients who had a partial response in clinical trials. Individual patient responses may vary.
Partial response
- laCSCC
- Not a candidate for curative surgery or curative radiation
- 70-year-old male
Cranial lesion
Screening
After 16 weeks
After 24 weeks
After 32 weeks
Auricular lesion
Screening
After 16 weeks
After 24 weeks
After 32 weeks
Auricular lesion
(enlarged view)
Screening
After 16 weeks
After 24 weeks
After 32 weeks
Partial response
- laCSCC
- Not a candidate for curative surgery or curative radiation
- 57-year-old male
Auricular lesion
Screening
After 16 weeks
After 24 weeks
After 32 weeks
After 40 weeks
Partial response
Supraclavicular
lesion
Screening
After 8 weeks
After 24 weeks
After 40 weeks
Partial response
Clavicular lesions
Screening
After 8 weeks
After 24 weeks
After 48 weeks
- LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC.
- Data on file. Regeneron Pharmaceuticals Inc.